AbCellera Biologics Inc. (ABCL)
Sector: Pharmaceutical Preparations
Industry: Biotechnology
AbCellera Biologics Inc.
NASDAQ:ABCLHealthcare · Biotechnology
PrePre-market+0.51%$11.94
Close$11.88-0.16%AH$11.86+0.66%Now$11.94
Close$11.88+6.74%AH$11.86+0.66%since
Mkt Cap$3.85B
Float212.82M
O/S324.05M
PM VOL17K sh
$ Vol≈$199K
RVOL0.71×
Inst Own35.3%
SI14.5%
Dilution
Historical Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 6, 2026 | 11.56 | 11.98 | 11.20 | 11.88 | 2,210,673 |
| Nov 5, 2026 | 11.88 | 11.88 | 10.76 | 11.13 | 4,149,514 |
| Nov 4, 2026 | 12.32 | 12.54 | 11.53 | 12.28 | 2,671,257 |
| Nov 3, 2026 | 11.32 | 12.33 | 11.28 | 12.18 | 2,502,034 |
| Nov 2, 2026 | 12.33 | 12.33 | 11.05 | 11.12 | 3,037,020 |
| Oct 30, 2026 | 12.65 | 12.91 | 11.75 | 12.27 | 3,876,554 |
| Oct 29, 2026 | 13.41 | 13.86 | 13.02 | 13.08 | 2,618,444 |
| Oct 28, 2026 | 12.67 | 13.65 | 12.65 | 13.64 | 3,058,614 |
| Oct 27, 2026 | 11.98 | 12.89 | 11.85 | 12.83 | 3,460,357 |
| Oct 26, 2026 | 12.02 | 12.41 | 11.78 | 12.08 | 3,038,418 |
| Oct 23, 2026 | 11.45 | 11.89 | 11.08 | 11.82 | 3,032,550 |
| Oct 22, 2026 | 11.98 | 12.23 | 11.21 | 11.37 | 4,277,111 |
| Oct 21, 2026 | 11.78 | 12.37 | 11.59 | 12.24 | 3,216,083 |
| Oct 20, 2026 | 11.65 | 11.95 | 11.41 | 11.71 | 4,263,276 |
| Oct 19, 2026 | 12.04 | 12.28 | 11.75 | 11.93 | 3,136,992 |
| Oct 16, 2026 | 12.68 | 12.68 | 11.72 | 11.80 | 4,112,109 |
| Oct 15, 2026 | 11.94 | 12.86 | 11.69 | 12.68 | 5,759,737 |
| Oct 14, 2026 | 12.37 | 12.84 | 12.26 | 12.37 | 3,058,826 |
| Oct 13, 2026 | 12.53 | 12.72 | 12.20 | 12.61 | 3,254,184 |
| Oct 12, 2026 | 12.71 | 13.05 | 12.43 | 12.63 | 5,756,294 |
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target
Not availableRatings Distribution
BUY9
HOLD2
SELL0
TOTAL11
Insider Trades
| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Hayden Michael R | Director | Purchase | 53.6K | $570.4K | Aug 24, 2026 |
 Montalbano John S. | Director | Purchase | 10.0K | $110.3K | Aug 18, 2026 |
 Booth Andrew | Chief Financial Officer | Purchase | 37.2K | $383.9K | Aug 14, 2026 |
| Hayden Michael R | Director | Purchase | 46.4K | $481.0K | Aug 12, 2026 |
| Hayden Michael R | Director | Withholding/Transfer | 50.0K | -- | Aug 11, 2026 |
 Seely Lynn | Director | Grant/Award | 152.2K | -- | Jul 1, 2026 |
Shareholders
35.3%
Institutional
(144)
17.7%
Insiderⓘ
(4)
18.7%
5%+ Owners
(1)
of which 18.7% rests on schedules older than 24 months (1 holder)
28.3%
Unattributed (incl. retail)ⓘ
Institutional35.3%
Insider17.7%
5%+ Beneficial18.7%
Unattributed (incl. retail)28.3%
Top Shareholders
| Name | Shares | % | Source |
|---|---|---|---|
Carl L.G. Hansen 2. · may incl. warrants· stale · filed Feb 2024 | 60.7M | 18.7% | 13G |
 Thermopylae Holdings Ltd. 10% Owner | 56.1M | 17.3% | FORM 4 |
Baker Bros. Advisors LP · also on 13F· joint filing· may incl. warrants· filed May 2026 | 33.0M | 10.2% | 13G |
BAKER BROS. ADVISORS LP | 33.0M | 10.2% | 13F |
Capital World Investors | 13.6M | 4.2% | 13F |
BAILLIE GIFFORD & CO · filed Oct 2024 | 12.9M | 4.0% | 13G |
TWO SIGMA INVESTMENTS, LP | 10.4M | 3.2% | 13F |
TD Waterhouse Canada Inc. | 9.2M | 2.8% | 13F |
BANK OF AMERICA CORP /DE/ | 6.1M | 1.9% | 13F |
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 4.3M | 1.3% | 13F |
Sources: 13F, Form 4, 13D/13GO/S: 324.0M · checked 9 Nov 2026 · market-data provider
Insiders & Institutional Holders
Insiders
- Hayden Michael RDirector
- Montalbano John S.Director
- Booth AndrewChief Financial Officer
- Seely LynnDirector
- Sandor VictorDirector
- Quake StephenDirector
- Thermopylae Holdings Ltd.10% Owner
- Hansen Carl L. G.Chief Executive Officer
- Lecault VeroniqueChief Technology Officer
- Stimart TrynChief Legal Officer
Top institutional holders
About
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Key Metrics
Market Cap$3.85B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership35.31%
based on 324.05M shares outstanding
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
Country
CA
CAIPO DateDec 11, 2020
Shares Outstanding324.05M
Authorized Shares
Float212.82M
52-Week Range
$2.75$15.02
$11.88(74th percentile)
Volume
Average Daily Volume3.52M
2.21M today vs 3.52M avg(-37%)
30d Avg
3.52M
60d Avg
4.57M
90d Avg
5.37M
Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...